Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of Senti-202, a Logic Gated, Selective Cd33/Flt3-Targeting Car-Nk Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including Aml

THOMSON REUTERS
02 Dec 2024

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of Senti-202, a Logic Gated, Selective Cd33/Flt3-Targeting Car-Nk Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including Aml

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10